Skip to main content

Advertisement

SpringerLink
Log in

Intravesical gemcitabine for treatment of superficial bladder cancer not responding to Bacillus Calmette-Guérin vaccine

  • Original Article
  • Published:
African Journal of Urology Submit manuscript

Abstract

Objectives

Intravesical Bacillus Calmette-Guérin (BCG) vaccine is the mainstay of treatment and prophylaxis in superficial bladder cancer (SBC) as it reduces tumor recurrence and disease progression. About one-third of patients do not respond to BCG. The aim of this study was to determine the efficacy of intravesical gemcitabine in patients with BCG-refractory SBC.

Methods

Twenty three patients with SBC; TaG3, T1G2-G3 or carcinoma in situ (CIS), refractory (after at least 2 courses of intravesical BCG) or intolerant to intravesical BCG therapy were included. Two weeks after complete tumor resection, patients received intravesical gemcitabine twice weekly at a dose of 2.000 mg/100 ml normal saline for 6 consecutive weeks. Two months after the last dose, recurrence-free patients underwent cystoscopy, urinary cytology and 6 random bladder biopsies. Thereafter, patients were evaluated by the same measures every 3 months, as long as there was no recurrence. Patients with complete response (negative cytology and random biopsies) at the first follow-up cystoscopy received a similar maintenance dose once weekly for another 6 weeks.

Results

Twenty one patients completed the study: 15 males and 6 females with a mean age of 48.1 (38–72) years. The follow-up was 15 months (range 2–19 months). Thirteen (61.9%) patients were recurrence-free after a mean of 17 months. Superficial recurrences were detected in 6 (28.6%) patients and progression by stage in 2 patients (9.5%). During follow-up, 8 patients had tumor recurrences and 2 had progression to a higher stage. The median recurrence-free time was 14.7 months (5–19 months). The drug was well tolerated and side-effects were mild in all patients, except two: one had easily controlled hematuria and the other had leucopenia.

Conclusion

In properly selected patients, gemcitabine seems to be a promising option in the management of high-risk BCG-refractory SBC, especially in those who refuse or are unfit for cystectomy. Long-term efficacy and the role of maintenance therapy have to be properly studied.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Kirkali Z, Chan T, Manoharan M, Algaba F, Busch C, Cheng L, et al. Bladder cancer: Epidemiology, staging and grading and diagnosis. Urology. 2005; Dec;66(6 Suppl 1):4–34.

    Article  PubMed  Google Scholar 

  2. Devesa SS, Blot WJ, Stone BJ, Miller BA, Tarone RE, Fraumeni JF, Jr. Recent cancer trends in the United States. J.Natl.Cancer Inst. 1995; Feb 1;87(3):175–182.

    Article  PubMed  CAS  Google Scholar 

  3. Crawford ED. Intravesical therapy for superficial cancer: Need for more options. J.Clin.Oncol. 2002; Aug 1;20(15):3185–3186.

    PubMed  Google Scholar 

  4. Gontero P, Marini L, Frea B. Intravesical gemcitabine for superficial bladder cancer: Rationale for a new treatment option. BJU Int. 2005; Nov;96(7):970–976.

    Article  PubMed  CAS  Google Scholar 

  5. Mohanty NK, Nayak RL, Vasudeva P, Arora RP. Management of BCG non-responders with fixed dose intravesical gemcitabine in superficial transitional cell carcinoma of urinary bladder. Indian J.Urol. 2008;24(1):44–47.

    Article  PubMed  CAS  Google Scholar 

  6. Lamm DL. Long-term results of intravesical therapy for superficial bladder cancer. Urol.Clin.North Am. 1992; Aug;19(3):573–580.

    PubMed  CAS  Google Scholar 

  7. Cozzi PJ, Bajorin DF, Tong W, Nguyen H, Scott J, Heston WD, et al. Toxicology and pharmacokinetics of intravesical gemcitabine: A preclinical study in dogs. Clin.Cancer Res. 1999; Sep;5(9):2629–2637.

    PubMed  CAS  Google Scholar 

  8. Redorta JP. Bacillus Calmette-Guérin (BCG) into the bladder has been demonstrated as an efficacious adjuvant treatment for superficial bladder cancer. European urology — Management of BCG? Failures? Eur.Urol. 2006.

  9. Peyromaure M, Guerin F, Amsellem Ouazana D, Saighi D, Debre B, Zerbib M. Intravesical bacillus Calmette-Guerin therapy for stage T1 grade 3 transitional cell carcinoma of the bladder: Recurrence, progression and survival in a study of 57 patients. J.Urol. 2003; Jun;169(6):2110–2112.

    Article  PubMed  CAS  Google Scholar 

  10. Shahin O, Thalmann GN, Rentsch C, Mazzucchelli L, Studer UE. A retrospective analysis of 153 patients treated with or without intravesical bacillus Calmette-Guerin for primary stage T1 grade 3 bladder cancer: Recurrence, progression and survival. J.Urol. 2003; Jan;169(1):96,100; discussion 100.

    Article  PubMed  CAS  Google Scholar 

  11. Malavaud B. T1G3 bladder tumours: The case for radical cystectomy. Eur.Urol. 2004; Apr;45(4):406–410.

    Article  PubMed  Google Scholar 

  12. Lerner SP. Treatment of high-risk, non-muscle-invasive bladder cancer. Nat.Clin.Pract.Urol. 2006; Aug;3(8):398–399.

    Article  PubMed  Google Scholar 

  13. Perabo FG, Muller SC. New agents in intravesical chemotherapy of superficial bladder cancer. Scand.J.Urol. Nephrol. 2005;39(2):108–116.

    Article  PubMed  CAS  Google Scholar 

  14. Stadler WM, Kuzel T, Roth B, Raghavan D, Dorr FA. Phase II study of single-agent gemcitabine in previously untreated patients with metastatic urothelial cancer. J.Clin.Oncol. 1997; Nov;15(11):3394–3398.

    PubMed  CAS  Google Scholar 

  15. Lorusso V, Pollera CF, Antimi M, Luporini G, Gridelli C, Frassineti GL, et al. A phase II study of gemcitabine in patients with transitional cell carcinoma of the urinary tract previously treated with platinum. Italian cooperative group on bladder cancer. Eur.J.Cancer. 1998; Jul;34(8):1208–1212.

    Article  PubMed  CAS  Google Scholar 

  16. Bassi P, De Marco V, Tavolini IM, Longo F, Pinto F, Zucchetti M, et al. Pharmacokinetic study of intravesical gemcitabine in carcinoma in situ of the bladder refractory to bacillus Calmette-Guerin therapy. Urol.Int. 2005;75(4):309–313.

    Article  PubMed  CAS  Google Scholar 

  17. Gontero P, Casetta G, Maso G, Sogni F, Pretti G, Zitella A, et al. Phase II study to investigate the ablative efficacy of intravesical administration of gemcitabine in intermediate-risk superficial bladder cancer (SBC). Eur. Urol. 2004;46(3):339–343.

    Article  PubMed  CAS  Google Scholar 

  18. Dalbagni G, Russo P, Bochner B, Ben Porat L, Sheinfeld J, Sogani P, et al. Phase II trial of intravesical gemcitabine in bacille Calmette-Guerin-refractory transitional cell carcinoma of the bladder. J.Clin.Oncol. 2006; Jun 20;24(18):2729–2734.

    Article  Google Scholar 

  19. Gacci M, Bartoletti R, Cai T, Nerozzi S, Pinzi N, Repetti F, et al. Intravesical gemcitabine in BCG-refractory T1G3 transitional cell carcinoma of the bladder: A pilot study. Urol.Int. 2006;76(2):106–111.

    Article  PubMed  CAS  Google Scholar 

  20. Montella L, Addeo R, Bellini S, Faiola V, Tarantino L, Pizza C, et al. Intravesical gemcitabine versus mitomycin for recurrent superficial bladder tumors (Stages pTa and pT1): A randomized prospective study. J.Clin.Oncol. 2008;26.

  21. Mattioli F, Curotto A, Manfredi V, Gosmar M, Garbero C, Ambruosi C, et al. Intravesical gemcitabine in superficial bladder cancer: A phase II safety, efficacy and pharmacokinetic study. Anticancer Res. 2005; May–Jun;25(3c):2493–2496.

    PubMed  CAS  Google Scholar 

  22. Bounedjar A, Ferhat R, Smaili F, Bouzid K. Results at 5 years of intra vesical gemcitabine (G) single agent as adjuvant chemotheray in superficial Transitional Cell Carcinoma (TCC) of the bladder. J.Clin.Oncol. 2009;27:e16087.

    Google Scholar 

  23. Bartoletti R, Cai T, Gacci M, Giubilei G, Viggiani F, Santelli G, et al. Intravesical gemcitabine therapy for superficial transitional cell carcinoma: Results of a phase II prospective multicenter study. Urology. 2005; Oct;66(4):726–731.

    Article  PubMed  Google Scholar 

  24. Dalbagni G, Russo P, Sheinfeld J, Mazumdar M, Tong W, Rabbani F, et al. Phase I trial of intravesical gemcitabine in bacillus Calmette-Guerin-refractory transitional-cell carcinoma of the bladder. J.Clin.Oncol. 2002; Aug 1;20(15):3193–3198.

    Article  PubMed  CAS  Google Scholar 

  25. Gunelli R, Bercovich E, Nanni O, Ballardini M, Frassineti GL, Giovannini N, et al. Activity of endovesical gemcitabine in BCG-refractory bladder cancer patients: A translational study. Br.J.Cancer. 2007;97(11):1499–1504.

    Article  PubMed  CAS  Google Scholar 

  26. Bounedjar A, Ferhat R, Smaili F, Bouzid K. Intra vesical gemcitabine (G) single agent as adjuvant chemotherapy in superficial Transitional Cell Carcinoma (TCC) of the bladder: Final results. J.Clin.Oncol. 2007;25(18S):5078.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Urology, Faculty of Medicine, Suez Canal University, Ismailia, Egypt

    Mohamed Ali Elkoushy

Authors
  1. Mohamed Ali Elkoushy
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mohamed Ali Elkoushy.

About this article

Cite this article

Elkoushy, M.A. Intravesical gemcitabine for treatment of superficial bladder cancer not responding to Bacillus Calmette-Guérin vaccine. Afr J Urol 16, 110–116 (2010). https://doi.org/10.1007/s12301-010-0024-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12301-010-0024-5

Key Words

Search

Navigation